Aller au contenu principal
Profil bibliographique

Jadel Muller Kratz

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

74Publications signalées
1913Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Research on Leishmaniasis StudiesTrypanosoma species research and implicationsDrug Solubulity and Delivery SystemsSynthesis and Biological EvaluationComputational Drug Discovery Methods

Les publications récentes

Accès ouvert 2026 article OpenAlex

Identification of new Trypanosoma cruzi-specific protein synthesis inhibitors by using a developed high-throughput in vitro translation assay

Camila Colombari Mantovani, Flávia Regina Novais de Freitas, Carolina Borsoi Moraes, Guilherme Rodrigo Reis Monteiro dos Santos et autres

There are restricted treatment options for Chagas disease, a global health risk causing 12,000 fatalities annually. This situation is exacerbated by environmental changes and migration, which is altering patterns of disease transmission, and by expansion of the vector range. The disease is …

br, us, ch (code pays fourni par la source)

0 citations International Journal for Parasitology Drugs and Drug Resistance
Accès ouvert 2026 article OpenAlex

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmaniasis

Rasmus Hansen Henninger, Wietse M. Schouten, Byron A. Arana, Jean‐Yves Gillon et autres

ABSTRACT Cutaneous leishmaniasis is a neglected tropical disease with only one oral treatment option. DNDI‐6148 is an orally bioavailable compound with potent antiparasitic activity in preclinical studies. Establishing skin target‐site pharmacokinetic/pharmacodynamic (PK/PD) relationships is essential to enable its clinical development. The objective …

se, nl, ch, gb (code pays fourni par la source)

0 citations Clinical and Translational Science
Accès ouvert 2025 article OpenAlex

Barbituric Acid Derivatives as Covalent Inhibitors of Leishmania braziliensis Dihydroorotate Dehydrogenase

Thamires Quadros Froes, Temitayo Omowumi Alegbejo Price, Bruna Fleck Godoi, Miguel de Menezes Vaidergorn et autres

Abstract Covalent drug design applied to parasite proteins enables selective therapies by targeting nucleophilic residues of macromolecules. We present the first covalent inhibitors of Leishmania braziliensis dihydroorotate dehydrogenase (LbDHODH), a key enzyme in pyrimidine biosynthesis with a reactive cysteine (Cys131) in its …

us, br, it, ch (code pays fourni par la source)

1 citation Journal of Medicinal Chemistry
Accès ouvert 2025 article OpenAlex

Validated LC‐MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI‐0690 in Preclinical Target Site PK/PD Studies

Wietse M. Schouten, Katrien Van Bocxlaer, Hilde Rosing, Alwin D. R. Huitema et autres

Understanding the target site pharmacokinetics (PK) of the nitroimidazole analog DNDI-0690, a potential drug for the neglected parasitic disease leishmaniasis, is important due to the diversity of infected tissue sites and potential drug penetration variability. An ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) …

nl, gb, ch, se (code pays fourni par la source)

0 citations Biomedical Chromatography
Accès ouvert 2025 article OpenAlex

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study

Wietse M. Schouten, Katrien Van Bocxlaer, Hilde Rosing, Alwin D. R. Huitema et autres

Leishmaniasis is a neglected parasitic infection that continues to pose a significant global health challenge, with currently limited effective treatment options. DNDI-6174 is a novel orally-active, investigational drug with antileishmanial properties. Herein, a novel ultra-high performance liquid chromatography coupled to tandem mass …

nl, gb, ch, se (code pays fourni par la source)

0 citations Journal of Chromatography B
Accès ouvert 2025 article OpenAlex

Discovery and Early Optimization of 1 H -Indole-2-carboxamides with Anti- Trypanosoma cruzi Activity

Ramon Guerra de Oliveira, Luiza R. Cruz, Marco A. Dessoy, Paul J. Koovits et autres

High Resolution Image Download MS PowerPoint Slide Chagas disease (CD), caused by the flagellate protozoan Trypanosoma cruzi, is a neglected tropical disease endemic in 21 countries. The only two antiparasitic drugs approved for its treatment, benznidazole and nifurtimox, have significant drawbacks. We …

br, ch, cz, us (code pays fourni par la source)

4 citations Journal of Medicinal Chemistry
Accès ouvert 2024 article OpenAlex

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices

Wietse M. Schouten, Katrien Van Bocxlaer, Hilde Rosing, Alwin D. R. Huitema et autres

• DNDI-6148 is a new potential oral compound for cutaneous leishmaniasis treatment. • First validated UPLC-MS/MS methods to quantify DNDI-6148 in multiple biomatrices. • Enzymatic digestion of mouse tissue was superior over mechanical homogenization. • Protein precipitation yielded reproducible recoveries, with no …

nl, gb, ch (code pays fourni par la source)

3 citations Journal of Chromatography B
2024 article OpenAlex

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

A. C Silva, Jadel Muller Kratz, Priscylla G. M. Morgado, Lucio Holanda Freitas-Junior et autres

To control and decrease the public health impact of human protozoan diseases such as Chagas disease, leishmaniasis, and human African trypanosomiasis, expediting the development of new drugs and vaccines is necessary. However, this process is filled with difficulties such as highly complex …

br, ch (code pays fourni par la source)

0 citations Journal of Visualized Experiments
Accès ouvert 2024 article OpenAlex

Synthesis and Anti-Trypanosoma cruzi Activity of 3-Cyanopyridine Derivatives

Brian W. Slafer, Marco A. Dessoy, Ramon Guerra de Oliveira, María C. Mollo et autres

High Resolution Image Download MS PowerPoint Slide Chagas disease (CD) is a parasitic neglected tropical disease (NTD) caused by the protozoan Trypanosoma cruzi that affects 6 million people worldwide, often resulting in financial burden, morbidity, and mortality in endemic regions. Given a …

br, be, ch (code pays fourni par la source)

1 citation ACS Omega
Accès ouvert 2024 article OpenAlex

AI is a viable alternative to high throughput screening: a 318-target study

Izhar Wallach, Denzil Bernard, Kong T. Nguyen, Gregory Ho et autres

High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy …

us, br, sg, au, ca, nl, ch, be, it, gb, es (code pays fourni par la source)

138 citations Scientific Reports
Accès ouvert 2023 article OpenAlex

Design, synthesis, and lead optimization of piperazinyl-pyrimidine analogues as potent small molecules targeting the viral capping machinery of Chikungunya virus

Verena Battisti, Julia Moesslacher, Rana Abdelnabi, Pieter Leyssen et autres

The worldwide re-emerge of the Chikungunya virus (CHIKV), the high morbidity associated with it, and the lack of an available vaccine or antiviral treatment make the development of a potent CHIKV-inhibitor highly desirable. Therefore, an extensive lead optimization was performed based on …

at, be (code pays fourni par la source)

8 citations European Journal of Medicinal Chemistry

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.